Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care ...( RICHMOND Calif. April 28 /- Transcept...)

RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the Bank of America and Merrill Lynch 2009 Health Care Conference in New York City on Tuesday, May 12, 2009 at 12:40 p.m., Eastern Time.

An audio webcast of the presentation will be available at www.transcept.com. The audio replay of the presentation will be available at the same location through May 26, 2009.

About Transcept Pharmaceuticals (TSPT)

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved as anticipated, Intermezzo(R) will be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA), which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the company's website at: